Radspherin

2022: Product Development

On August 25, 2022, the Norwegian company Oncoinvent AS, which is in the clinical stage of the development of therapy with alpha emitters in various types of cancer, announced that the first patient with colorectal cancer in a phase 2A RAD-18-002 clinical trial received treatment with the candidate drug Radspherin.

The overall study of patients is conducted at two sites: Radiy Hospital in Norway and Uppsala University Hospital in Sweden and will include a total of 30 patients. Phase 2A of the open-label clinical trial RAD-18-002 aimed at assessing the safety, tolerability, and antitumor activity of Radspherin.

A Norwegian company has created a drug that cures colorectal cancer. The first person has already recovered

Oncoinvent AS leverages internal manufacturing and supply chain capabilities to provide clinical supplies of radioisotopes. The company is promoting alpha particle-based therapy, a higher form of radiation with linear energy transfer that can destroy cancer cells. Oncoinvent AS's leading candidate is designed to treat metastatic cancers in body cavities, and its versatility allows it to be used to treat a variety of cancers.

{{quote 'The start of the Phase RAD-18-002 study 2A marks the next phase of development for both our Radspherin and Oncoinvent AS! This study takes us one step closer to achieving our main goal of developing effective therapies for cancer patients suffering from peritoneal carcinomatosis, "said Oncoinvent AS Chief Executive Officer Jan Alfheim. }} Radspherin is administered to the intraperitoneal cavity in patients with peritoneal carcinomatosis for colorectal carcinoma, after complete cytoreductive surgery and hyperthermic (or hot) intraperitoneal chemotherapy. Key objectives of the study include improving patient survival and the acute and long-term safety of the candidate drug.^[1]

Notes